Search

Your search keyword '"Platelet Engraftment"' showing total 1,258 results

Search Constraints

Start Over You searched for: Descriptor "Platelet Engraftment" Remove constraint Descriptor: "Platelet Engraftment"
1,258 results on '"Platelet Engraftment"'

Search Results

1. Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin.

2. Is post-transplant day + 14 immature reticulocyte fraction (IRF) a reliable surrogate marker for predicting early platelet engraftment in pediatric hematopoietic stem cell transplant?

3. The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma.

4. Clinical Impact of Recipient-Derived Isoagglutinin Levels in ABO-Incompatible Hematopoietic Stem Cell Transplantation.

5. Recombinant human thrombopoietin improves platelet engraftment after autologous hematopoietic stem cell transplantation in patients with aggressive lymphoma.

6. Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, non‐inferiority, randomized controlled trial.

7. Effect and safety of recombinant human thrombopoietin on haematopoietic reconstitution after allogeneic haematopoietic cell transplantation.

10. Immature platelet fraction levels predict the development of prolonged thrombocytopenia after haematopoietic stem cell transplantation.

11. Efficacy of Recombinant Human Thrombopoietin for the Treatment of Secondary Failure of Platelet Recovery After Allogeneic HSCT.

12. Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation.

13. Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients Following Treatment With Haploid Hematopoietic Stem Cell Transplantation using Modified Post-Transplantation Cyclophosphamide.

15. Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin.

16. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center.

17. Association of CD 34 positive cell dose with engraftment kinetics in autologous peripheral blood stem cell transplant patients of multiple myeloma

18. Infusion of haploidentical hematopoietic stem cells combined with mesenchymal stem cells for treatment of severe aplastic anemia in adult patients yields curative effects

19. Association of CD34 Cell Dose with 5-Year Overall Survival after Peripheral Blood Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies

20. Clinical Impact of Recipient-Derived Isoagglutinin Levels in ABO-Incompatible Hematopoietic Stem Cell Transplantation

21. Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution

25. Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis

26. Meloxicam with Filgrastim may Reduce Oxidative Stress in Hematopoietic Progenitor Cells during Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma

28. Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: Association with chronic graft-versus-host disease and survival outcome.

30. A retrospective comparative cohort study on the routine pre-engraftment use of granulocyte colony-stimulating factor in allogeneic hematopoietic stem cell transplantation

31. Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome

32. Cord blood index predicts engraftment and early non-relapse mortality in adult patients with single-unit cord blood transplantation

33. Impact of CD34+ Stem Cell Dose on Engraftment Period in Allogeneic Peripheral Blood Stem Cell Transplanted Patients

34. Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation

35. Immature platelet fraction as a predictor of platelet count recovery following allogeneic bone marrow transplantation

36. Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation

37. Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption

38. Influence of laboratory procedures on postthawing cell viability and hematopoietic engraftment after autologous peripheral blood stem cell transplantation

39. Non‐myeloablative human leukocyte antigen‐matched related donor transplantation in sickle cell disease: outcomes from three independent centres

40. The Efficacy of Eltrombopag Treatment in Patients who developed Platelet Engraftment Failure after Allogeneic Stem Cell Transplantation: A Single Center Experience

41. Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study

42. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation

43. Eltrombopag as first‐line treatment for thrombocytopenia among paediatric patients after allogeneic haematopoietic stem cell transplantation

44. Single-Agent Cyclosporine for Graft-versus-Host Disease Prophylaxis in Patients with Acquired Aplastic Anemia Receiving Fludarabine-Based Conditioning

45. Single UM171‐expanded cord blood transplant can cure severe idiopathic aplastic anemia in absence of suitable donors

46. Outcome of allogeneic hematopoietic stem cell transplantation for hypoplastic myelodysplastic syndrome

47. Recombinant human thrombopoietin promotes platelet engraftment after umbilical cord blood transplantation

48. Impact of the <scp>CD4</scp> : <scp>CD8</scp> ratio in bone marrow on stem cell mobilization and engraftment in autologous stem cell transplant patients

49. Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902

50. The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced‐intensity hematopoietic peripheral blood cell transplant – a retrospective study

Catalog

Books, media, physical & digital resources